RU2536976C1 - Method of treating mastitis in lactating sheep - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: invention relates to field of veterinary medicine and is intended for treatment of mastitis in sheep. method includes introduction of medication, containing antibiotic and chemical therapeutic substance, at the background of subcutaneous introduction of oxytocin in dose 10 U two times with 12-hour interval and above-udder novocaine blockade in accordance with D.D.Logvinov, by double introduction of 0.25% novocaine solution in dose 0.5 ml per 1 kg of body weight, with 48-hour interval. Used is preparation, which contains antibiotic norfloxacin as antimicrobial preparation, and dioxydin as chemical therapeutic substance, and additionally 1,2-propyleneflycol, polyvinylpyrrolidone low-molecular, disodium salt of tetraacetic acid ethylenediamine (trilon B), hydrochloric acid (0.1 mol/l) to pH 4.5, water for injections with the following component ratio, wt %: dioxydin - 1.0; norfloxacin - 5.0; 1,2-propyleneflycol - 19.8; polyvinylpyrrolidone low-molecular - 0.2; disodium salt of tetraacetic acid ethylenediamine (trilon B) - 0.01; hydrochloric acid (0.1 mol/l) to pH 4.5-5.5; water for injections - to 100.0. Preparation is introduced intramuscularly in dose o.1 ml/kg of body weight two times per day until clinical recovery, for all forms of mastitis.

EFFECT: claimed invention makes it possible to provide expressed therapeutic effect.

2 tbl, 2 ex

Description

The invention relates to veterinary medicine, in particular to veterinary obstetrics, and can be used to treat mastitis in sheep.

Inflammation of the mammary gland - mastitis in sheep is widespread. During the year, mastitis suffers from two to ten percent of ewes [Huseynov EM, Shabanov Sh.B., Hasanova K.B. Diagnosis and prevention of latent mastitis. Sheep breeding number 2. 1993. S. 37-38].

Mastitis in sheep occurs in most cases as a result of the ingestion of pathogenic microflora, mainly staphylococci, streptococci, and pasteurellas, into the mammary gland. Infection occurs when the animal is lying on an infected litter or when the lambs and then healthy sheep are sucked by the lambs, as well as through injuries of the udder and nipples caused by the lambs (Goncharov V.P. Prevention and treatment of mastitis in animals / V.P. Goncharov, V.A. Karpov, I.L. Yakimchuk // M. - 1987. - 207 p.).

Mastitis is mainly acute and manifests itself in the form of serous, catarrhal, purulent and hemorrhagic inflammation, as well as subclinically. The economic damage from this disease consists of a decrease in milk productivity, deterioration in milk quality, premature rejection of the uterine population, high incidence of young animals with gastrointestinal and respiratory diseases [Nikitin V.Ya. Mastitis in sheep in the Stavropol Territory. Proceedings of the Stavropol Agricultural Institute, issue 20, 1965].

For the treatment of patients with mastitis, ewes mainly use various antimicrobial agents containing antibiotics and sulfonamides.

A known analogue is a method of treating mastitis in sheep, which involves intramuscular injection of penicillin at a dose of 100000-200000 units three times a day and oral administration of norsulfazole 1-3 g per head 2 times a day and once a day simultaneously with intramuscular injection of an antibiotic into the affected the share of the udder after secretion is secreted through the nipple, 50,000-100,000 IU of penicillin or streptomycin dissolved in 10 ml of saline are injected, or oil-based bactericidal emulsions (masticide, mastisan A, B or E). To dilute the exudate of the udder, before using these preparations, a warm 1-2% solution of bicarbonate of soda is introduced through the nipple and discarded. The course of treatment is 3-4 days [http://webmvc.com/bolezn/livestock/infect/cattle/mastitis.php].

The disadvantage of this method of treatment is the multiplicity and complexity of the introduction of drugs.

A known method of treating mastitis in animals using bicillin-3. The antibiotic is dissolved in sterile saline and intramuscularly administered to the ewes at a dose of 10-20 thousand units per 1 kg of animal weight [Arkhangelsky II, Infectious mastitis of sheep, in the book: Diseases of sheep and goats, M., 1973].

The disadvantage of this method is the low effectiveness of the treatment.

The closest analogue is a method of treating mastitis in animals using the drug [RU 2180559 C1, A61K 9/10, 03.20.2002] of the following composition, g / ml administration dose: gentamicin sulfate 0.017; dioxidine 0.01; soft monoglyceride 0.03; solid monoglyceride 0.03; oil up to 1.0. The drug is prepared by dispersing an antibiotic powder in an oil base (oil with emulsifiers) in a colloid mill to obtain a uniform and stable suspension.

The disadvantage of the prototype is the low effectiveness of the treatment, since the drug is used only topically (administered through the nipple into the mammary gland).

It is known that clinically pronounced mastitis in sheep is characterized by the rapid development of the inflammatory process, accompanied by general inhibition of the animal, which is manifested by malaise of the animal, decreased appetite, increased heart rate and respiration, increased body temperature to 41.5 ° C. Therefore, treatment must be carried out using not only local, but also general antimicrobial therapy (Goncharov V.P. Prevention and treatment of mastitis in animals / V.P. Goncharov, V.A. Karpov, I.L. Yakimchuk // M. - 1987 .-- 207 p.).

The technical result of the invention is to increase the effectiveness of the treatment of mastitis in lactating sheep.

To achieve a technical result in a method of treating mastitis in lactating sheep, comprising administering a preparation containing an antibiotic and a chemotherapeutic substance, according to the invention, a preparation containing an antibiotic norfloxacin as an antimicrobial agent and dioxidine as well as an additional 1,2 -propylene glycol, low molecular weight polyvinylpyrrolidone, disodium salt of ethylenediamine tetraacetic acid (trilon B), hydrochloric acid (0.1 mol / l) to pH 4.5, water for injection cts in the following ratio of components, wt.%:

Dioxidine - 1.0;

Norfloxacin - 5.0;

1,2-propylene glycol - 19.8;

Polyvinylpyrrolidone low molecular weight - 0.2;

Disodium salt of ethylenediamine tetraacetic acid (Trilon B) - 0.01;

Hydrochloric acid (0.1 mol / L) to pH 4.5-5.5;

Water for injection - up to 100.0,

moreover, the drug is administered intramuscularly at a dose of 0.1 ml / kg body weight twice a day until clinical recovery, with all forms of mastitis.

Compared with the prototype, an essential distinguishing feature of the invention is that instead of gentamicin sulfate, the chemotherapeutic agent norfloxacin is used and the drug is administered intramuscularly.

The combination in the dosage form of two antimicrobial components with a different mechanism of action provides the best bactericidal and therapeutic effect by expanding the spectrum of antimicrobial action, preventing the formation of resistance of microorganisms. The dioxidine included in the preparation belongs to the quinoxaline series - 1,4-di-N-oxide-2,3-di (oxymethyl), quinoxaline - shows high antimicrobial activity against gram-negative and gram-positive microorganisms. Gram-negative microorganisms are most affected by dioxidine (“Temporary instruction on the use of dioxidine in veterinary medicine.” Approved by the General Directorate of Veterinary Medicine on November 5, 1991).

Norfloxacin is effective against gram-positive and gram-negative microorganisms: Escherichia, pasteurell, salmonella, staphylococcus, mycoplasma [Padeiskaya EN Fluoroquinolones. Broadly indicated drugs for treating bacterial infections. M .: 2005. - 79 p.].

Testing the method of treating mastitis in sheep was carried out on lactating ewes of the Dagestan rock, at 2-4 lamb, with a body weight of 3.5-40 kg, with subclinical, serous, catarrhal and purulent-catarrhal forms of mastitis. According to the principle of analogues, animals were divided into two groups, taking into account the general condition, the severity of the disease and the same feeding and keeping conditions.

The diagnosis of mastitis was established comprehensively on the basis of data from a clinical examination of animals, the results of bacteriological studies, taking into account the epizootic situation on the farm.

For the animals during the experiment conducted daily clinical observations. The treatment results were evaluated on the 3-4th day after the last injection of the drug comprehensively taking into account the clinical examination of sheep and laboratory studies of the secretion from the treated udder lobes. The studies were performed in two series of experiments.

Example 1. The study was conducted on 122 patients with mastitis ewes belonging to SEC them. Khizroev, Khunzakh region of the Republic of Dagestan.

The animals of the experimental group (n = 69) were injected intramuscularly with the preparation of the invention at a dose of 0.1 ml / kg of animal weight twice a day until clinical recovery, control (n = 53) - preparation of the following composition: g / ml administration dose: gentamicin sulfate 0.017; dioxidine 0.01; soft monoglyceride 0.03; solid monoglyceride 0.03; oil up to 1.0 in accordance with the instructions for use.

Tests of therapeutic efficacy were carried out against the background of subcutaneous administration of oxytocin at a dose of 10 PIECES twice with an interval of 12 hours and an elevated novocaine blockade according to DD Logvinov, by twice introducing a 0.25% solution of novocaine, at a dose of 0.5 ml per 1 kg of body weight, with an interval of 48 hours. The results of the experiment are presented in table 1.

Table 1 The effectiveness of the proposed method for the treatment of mastitis in lactating sheep in the SEC them. Khizroev Khunzakhsky region of the Republic of Dagestan Method of treatment Being treated, goal. Duration of recovery, days Recovered ewes % Subclinical mastitis The inventive method 22 2.3 ± 0.6 21 95.4 Prototype method 19 2.8 ± 0.6 17 89.4 Serous mastitis The inventive method 19 3.7 ± 0.3 eighteen 94.7 Prototype method 13 3.6 ± 0.7 eleven 84.6 Catarrhal mastitis The inventive method 16 3.9 ± 0.7 fifteen 93.7 Prototype method eleven 4.3 ± 0.3 9 81.8 Purulent catarrhal mastitis The inventive method 12 4,5 ± 0,6 10 83.3 Prototype method 10 4.7 ± 0.3 7 63.6

As follows from the data presented, the therapeutic effectiveness of the known method was: with subclinical mastitis - 89.4%, serous - 84.6%, catarrhal - 81.8%, purulent-catarrhal - 63.6%.

The highest therapeutic efficacy is achieved using the proposed method. With subclinical mastitis, it was 95.4%, serous - 94.7%, with catarrhal - 93.7%, with catarrhal-purulent - 83.3%, which is higher than when using the known method, respectively, 6.0%, 10.1%, 11.9% and 19.7%.

Example No. 2. The studies were performed on 99 patients with mastitis ewes belonging to the Agrofirm “Darada Murad” of the Gergebilsky district of the Republic of Dagestan.

The animals of the experimental group (n-54) were injected intramuscularly with the preparation according to the claimed method at a dose of 0.1 ml / kg of animal weight twice a day until clinical recovery, control (n = 45) - preparation of the following composition: g / ml administration dose: gentamicin sulfate 0.017; dioxidine 0.01; soft monoglyceride 0.03; solid monoglyceride 0.03; oil up to 1.0 in accordance with the instructions for use.

Tests of therapeutic efficacy were carried out against the background of subcutaneous administration of oxytocin at a dose of 10 PIECES twice with an interval of 12 hours and an elevated novocaine blockade according to DD Logvinov, by twice introducing a 0.25% solution of novocaine, at a dose of 0.5 ml per 1 kg of body weight, with an interval of 48 hours. The results of the experiment are presented in table 2.

The highest therapeutic efficacy is achieved using the proposed method. With subclinical mastitis, it was 94.7%, serous - 92.8%, with catarrhal - 90.9%, with purulent-catarrhal - 80.0%, which is higher than when using the known method, respectively, 7.2%, 11.0%, 20.9% and 17.5%.

Thus, the developed method for the treatment of mastitis in lactating sheep has a pronounced therapeutic effect. Its use is technologically and cost-effective.

table 2 The effectiveness of the proposed method for the treatment of mastitis in lactating sheep of Agrofirm "Darada Murad" Gergebilsky district of the Republic of Dagestan Preparations Being treated, goal. Duration of recovery, days Recovered ewes % Subclinical mastitis The inventive method 19 2.4 ± 0.7 eighteen 94.7 Prototype method 16 2.6 ± 0.1 fourteen 87.5 Serous mastitis The inventive method fourteen 3.3 ± 0.2 13 92.8 Prototype method eleven 3.6 ± 0.4 9 81.8 Catarrhal mastitis The inventive method eleven 3.7 ± 0.6 10 90.9 Prototype method 10 3.9 ± 0.3 7 70.0 Purulent catarrhal mastitis The inventive method 10 4,5 ± 0,8 8 80.0 Prototype method 8 4.4 ± 0.6 5 62.5

Claims (1)

A method for the treatment of mastitis in lactating sheep, including the introduction of a drug containing an antibiotic and chemotherapeutic substance, against the background of subcutaneous administration of oxytocin at a dose of 10 PIECES twice with an interval of 12 hours and impregnated novocaine blockade according to D. D. Logvinov, by double administration of a 0.25% solution of novocaine, at a dose of 0.5 ml per 1 kg of body weight, with an interval of 48 hours, characterized in that they use a drug containing the antibiotic norfloxacin as an antimicrobial agent, and as a chemotherapeutic substances - dioxidine, and also additionally - 1,2-propylene glycol, low molecular weight polyvinylpyrrolidone, disodium salt of ethylenediamine tetraacetic acid (Trilon B), hydrochloric acid (0.1 mol / l) to pH 4.5, water for injection in the following ratio of components , wt.%:
dioxidine - 1.0;
norfloxacin - 5.0;
1,2-propylene glycol - 19.8;
low molecular weight polyvinylpyrrolidone - 0.2;
disodium salt of ethylenediamine tetraacetic acid (trilon B) - 0.01;
hydrochloric acid (0.1 mol / l) to a pH of 4.5-5.5;
water for injection - up to 100.0,
moreover, the drug is administered intramuscularly at a dose of 0.1 ml / kg body weight twice a day until clinical recovery, with all forms of mastitis.